98187-16-7

Upstream product

• 320-36-5 4-nitro-3-trifluoromethylbenzonitrile 
• 320-38-7 4-nitro-3-(trifluoromethyl)benzoic acid 

Downstream Products

• 945028-63-7 N-[4-methyl-3-(4-pyridin-3-ylpyrimidin-2-ylamino)phenyl]-4-nitro-3-trifluoromethylbenzamide 
• 1239439-67-8 4-nitro-3-trifluoromethyl-N-(4-hydroxy-2-nitrophenyl)benzamide 
• 1287722-57-9 4-nitro-3-trifluoromethyl-N-(2-nitrophenyl)benzamide 
• 1275595-26-0 C₃₅H₄₃F₃N₁₀O₁₀ 
• 1384853-63-7 4-nitro-3-trifluoromethylbenzoyl-c(RGDfK) 
• 1384853-64-8 4-nitro-3-trifluoromethylbenzoyl-E[c(RGDfK)2] 
• 478797-87-4 4-nitro-N-phenyl-3-(trifluoromethyl)benzamide 
• 1073494-23-1 morpholino(4-nitro-3-(trifluoromethyl)phenyl)methanone 
• 945028-65-9 C₂₄H₁₉F₃N₆O 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione as antimycobacterial agents

Resistance among dormant mycobacteria leading to multidrug-resistant and extremely drug-resistant tuberculosis is one of the major threats. Hence, a series of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione derivatives (4a–5c) have been synthesized and screened for their antitubercular activity against Mycobacterium tuberculosis H37Ra (H37Ra). The triazolethiones 4b and 4v showed high antitubercular activity (both MIC and IC50) against the dormant H37Ra by in vitro and ex vivo. They were shown to have more specificity toward mycobacteria than other Gram-negative and Gram-positive pathogenic bacteria. The cytotoxicity was almost insignificant up to 100?μg/ml against THP-1, A549, and PANC-1 human cancer cell lines, and solubility was high in aqueous solution, indicating the potential of developing these compounds further as novel therapeutics against tuberculosis infection.

UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS

Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the compounds are useful in the treatment of diseases or disorders that are AR negative.

The flocculated acryloyldimethyltauric molecule ligand

Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

ONE-STEP 18F LABELING OF BIOLOGICAL SUBSTRATES AND USES OF 18F LABELED BIOLOGICAL SUBSTRATES

Disclosed is a rapid one-step 18F radiolabeling method for biological substrates that contain a specific arene group activated for nucleophilic aromatic substitution with 18F. The method involves reacting a biological substrate havin

Rapid and simple one-step F-18 labeling of peptides

Labeling biomolecules with 18F is usually done through coupling with prosthetic groups, which requires several time-consuming radiosynthesis steps and therefore in low labeling yield. In this study, we designed a simple one-step 18F-

Physical gelation of polar aprotic solvents induced by hydrogen bonding modulation of polymeric molecules

Poly(aryl ether amide) containing o-nitroanilide forms a physical gel in polar aprotic solvents by solvent-induced change of hydrogen bonding modes, in which hydrogen bonding acceptor solvent molecules break intramolecular hydrogen bonding of o-nitroanili

Optimization of novel combi-molecules: Identification of balanced and mixed bcr-abl/DNA targeting properties

Steps toward the identification of combi-molecules with strong abl tyrosine kinase (TK) inhibitory property and significant DNA damaging potential are described. The optimized combi-molecule 13a was shown to induce approximately twofold stronger abl TK in